MultiQure (MQR) Stock Overview
A biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MQR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
MultiQure S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.14 |
| 52 Week High | zł7.77 |
| 52 Week Low | zł1.35 |
| Beta | 0.21 |
| 1 Month Change | 45.71% |
| 3 Month Change | n/a |
| 1 Year Change | -52.71% |
| 3 Year Change | -83.98% |
| 5 Year Change | -96.82% |
| Change since IPO | -86.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| MQR | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 11.7% | 0.7% | 1.0% |
| 1Y | -52.7% | -9.3% | 29.7% |
Return vs Industry: MQR underperformed the Polish Biotechs industry which returned -9.3% over the past year.
Return vs Market: MQR underperformed the Polish Market which returned 29.7% over the past year.
Price Volatility
| MQR volatility | |
|---|---|
| MQR Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 10.3% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: MQR's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: MQR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 7 | Filip Jelen | purebiologics.com |
MultiQure S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was formerly known as Pure Biologics S.A. and changed its name to MultiQure S.A. in August 2026.
MultiQure S.A. Fundamentals Summary
| MQR fundamental statistics | |
|---|---|
| Market cap | zł38.45m |
| Earnings (TTM) | -zł9.10m |
| Revenue (TTM) | n/a |
Is MQR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MQR income statement (TTM) | |
|---|---|
| Revenue | zł0 |
| Cost of Revenue | zł26.00k |
| Gross Profit | -zł26.00k |
| Other Expenses | zł9.07m |
| Earnings | -zł9.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Sep 30, 2026
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -100.3% |
How did MQR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/12 23:02 |
| End of Day Share Price | 2026/08/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MultiQure S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sylwia Jaskiewicz | Dom Maklerski Banku Ochrony Srodowiska S.A. |